| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2017 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES NASDAQ BIOTECHNOLOGY | 15 | Q2 2024 | 7.7% |
| AVALONBAY COMMUNITIES INC | 15 | Q2 2024 | 2.3% |
| EQUITY RESIDENTIAL | 15 | Q2 2024 | 2.3% |
| INVESCO QQQ TRUST SERIES 1 | 14 | Q2 2024 | 29.1% |
| ISHARES MSCI JAPAN ETF | 14 | Q1 2024 | 14.8% |
| VANGUARD REAL ESTATE ETF | 14 | Q1 2024 | 6.0% |
| VANGUARD FTSE EUROPE ETF | 12 | Q2 2024 | 18.9% |
| VANECK SEMICONDUCTOR ETF | 12 | Q2 2024 | 8.8% |
| BLOOMIN' BRANDS INC | 12 | Q2 2024 | 4.2% |
| GRAYSCALE ETHEREUM TRUST | 12 | Q2 2024 | 11.3% |
View Rye Brook Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-07-22 |
| 13F-HR | 2024-04-11 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-10 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-21 |
| 13F-HR | 2023-01-06 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-07-21 |
| 13F-HR | 2022-04-28 |
View Rye Brook Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.